Myomo Inc
F:0M61
Myomo Inc
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.
Revenue: Myomo reported Q3 2025 revenue of $10.1 million, hitting the high end of expectations and up 10% year-over-year.
Guidance Reiterated: Full-year 2025 revenue guidance remains at $40 million to $42 million, representing more than 23% growth over last year.
International & O&P Growth: International revenue, mainly from Germany, hit a record $1.8 million (up 63%), and O&P channel revenue doubled to $900,000.
Pipeline Expansion: Patient pipeline grew 32% year-over-year; new programs like MyoConnect and expanding clinician training are driving higher-quality leads.
Margins & Costs: Gross margin declined to 63.8% (from 75.4% last year) due to higher costs and a prior accounting change, but manufacturing improvements are underway.
Operating Loss: Net loss widened to $3.7 million ($0.09 per share) from $1 million in Q3 2024, with operating expenses up 26% year-over-year.
New Debt Facility: Secured a $17.5 million term loan to support future growth, with $12.5 million funded at closing.
Strategic Focus: The company is shifting from advertising-driven growth to recurring referrals from clinicians and O&P partners to lower acquisition costs and improve profitability.
